Interpretation of updated NCCN guidelines for small cell lung cancer (version 1. 2022)
10.7507/1007-4848.202109043
- VernacularTitle:2022 年 V1 版《NCCN 小细胞肺癌临床实践指南》更新解读
- Author:
Zheng JIAN
1
;
Yajie ZHANG
1
;
Jiahao ZHANG
1
;
Hecheng LI
1
Author Information
1. Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P.R.China
- Publication Type:Journal Article
- Keywords:
Small cell lung cancer;
NCCN guidelines;
update of version 1, 2022;
interpretation of guideline
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2021;28(11):1272-1276
- CountryChina
- Language:Chinese
-
Abstract:
The National Comprehensive Cancer Network (NCCN) released the latest version 1, 2022 of "NCCN guidelines for the clinical diagnosis and treatment of small cell lung cancer" (hereinafter referred to as "guideline"). Based on high-quality evidence-based medicine, this guideline provides references of clinical diagnosis and treatment for clinicians around the world. Compared with the version 3, 2021 of the "guideline", updates and revisions mainly focused on the progress of radiotherapy and systemic treatment. This article will interpret the updated therapy content in this new version of the "guideline".
